Subir Nag, MD

Articles

Subir Nag, MD;Jason F. Kelly, MD;John L. Horton, PhD;Ritsuko Komaki, MD;Dattatreyudu Nori, MD

March 1st 2001

An estimated 157,000 patients died of lung cancer in the United States in the year 2000.[1] Although surgery can be curative, only about 20% of patients are amenable to complete surgical resection. Most of the other patients are treated with radiation

Brachytherapy in the Treatment of Breast Cancer

Subir Nag, MD;Robert R. Kuske, MD;Frank A. Vicini, MD;Douglas W. Arthur, MD;Robert D. Zwicker, PhD

February 1st 2001

Whole-breast external-beam radiation therapy (EBRT) involves a 6-week course of fractionated treatments. In

Use of Brachytherapy to Preserve Function in Children With Soft-Tissue Sarcomas

Subir Nag, MD;Patrick S. Fernandes, MD;Rafael Martinez-monge, MD;Frederick B. Ruymann, MD

March 1st 1999

Pediatric soft-tissue sarcomas are managed with a multimodality treatment program that includes surgery, chemotherapy, and external-beam radiotherapy (teletherapy). The use of teletherapy in young children can

Commentary (Nag): High-Dose-Rate Intraoperative Radiation Therapy For Colorectal Cancer

Subir Nag, MD

July 1st 1995

In this issue, Harrison et al give the rationale for intraoperative high-dose-rate brachytherapy (IOHDR) and provide an excellent summary of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience with this treatment. Intraoperative high-dose-rate brachytherapy is used in very few centers [1-4], and its worldwide use has been recently summarized [5,6]. Although our experience with IOHDR at Ohio State University parallels that of Harrison et al in some respects, it differs in others. I will highlight these differences to give readers a more balanced view of IOHDR.